HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
03 janv. 2024 16h15 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), would like to remind its shareholders to...
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
14 déc. 2023 16h15 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered...
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
05 déc. 2023 08h00 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered...
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
20 nov. 2023 08h00 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered...
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
13 nov. 2023 08h45 HE
|
Heart Test Laboratories, Inc.
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology...
HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments
19 oct. 2023 09h00 HE
|
Heart Test Laboratories, Inc.
Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA...
HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
26 sept. 2023 08h00 HE
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology...
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
25 sept. 2023 08h00 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based...
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
21 sept. 2023 08h00 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an AI-powered medical technology company...
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
14 sept. 2023 16h15 HE
|
Heart Test Laboratories, Inc.
Southlake, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based...